Chimeric’s $1.8M Funding Advance: What Risks Lie Ahead?
Chimeric Therapeutics has secured a $1.785 million advance against its anticipated FY26 Research and Development Tax Incentive to bolster its clinical trial pipeline and working capital.
- Secured $1.785 million advance from Radium Capital
- Funding backed by anticipated FY26 R&D Tax Incentive
- Supports clinical trials and general working capital
- Repayment due by 31 December 2026 with commercial interest
- Company advancing multiple oncology-focused cell therapy programs
Funding Boost for Clinical Pipeline
Chimeric Therapeutics, a clinical-stage Australian cell therapy company, has announced it received $1.785 million in advance funding from Radium Capital. This facility is secured against the company’s anticipated Research and Development Tax Incentive (RDTI) for the 2026 financial year, providing early access to government-backed funds.
The injection of capital is earmarked to support Chimeric’s ongoing clinical trial programs as well as general working capital needs. This move reflects the company’s strategic approach to managing cash flow while progressing its innovative oncology therapies.
Structure and Terms of the Facility
The funding agreement stipulates that the advance is secured against the expected FY26 RDTI refund from the Australian Taxation Office, which offers a refundable tax offset of up to 43.5% for eligible R&D activities. Interest on the facility is charged at a commercial rate, with repayment scheduled following receipt of the RDTI, due by 31 December 2026. Notably, Chimeric can repay the facility earlier without penalty after a minimum interest period of 90 days.
Advancing Cell Therapy Innovations
Chimeric is advancing a diversified portfolio of cell therapies targeting cancer, including autologous CAR T cell and allogeneic natural killer (NK) cell therapies. Its programs include CHM CDH17, a first-in-class CAR T therapy developed at the University of Pennsylvania, currently in phase 1/2 trials for gastrointestinal and neuroendocrine tumours.
Additionally, the company’s CORE-NK platform has demonstrated safety and efficacy in blood cancers and solid tumours, with ongoing phase 1B trials exploring combination regimens. Another promising asset, CHM CLTX, is in phase 1B trials targeting glioblastoma, with encouraging early data reported last year.
Strategic Implications
This funding advance not only provides Chimeric with immediate liquidity but also underscores the company’s ability to leverage government incentives to support its R&D pipeline. As clinical milestones approach, maintaining financial flexibility will be critical for sustaining momentum in a competitive biotech landscape.
Bottom Line?
Chimeric’s strategic funding move sets the stage for continued clinical progress and financial resilience through 2026.
Questions in the middle?
- What are the detailed terms and interest rates of the Radium Capital facility?
- How will the timing of RDTI receipt impact Chimeric’s cash flow and trial timelines?
- What upcoming clinical milestones could influence further funding needs?
